ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6069 articles about ACCESSWIRE
-
CARDIO inCode-Score Clinical Publication on Polygenic Risk of Coronary Heart Disease
4/5/2024
GENinCode Plc (www.genincode.com) the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces today the publication by the American Journal of Preventive Cardiology of a study on ‘Polygenic Risk and Incident Heart Disease in a large multiethnic cohort'
-
BioInvent International AB Publishes Annual Report 2023
4/4/2024
BioInvent International AB today announced that the Annual Report for 2023 has been published.
-
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
4/4/2024
Vicore Pharma Holding The shareholders of Vicore Pharma Holding AB, Reg. No. 556680-3804, with its registered offices in Stockholm, are summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 in the premises of the law firm Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden.
-
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
4/4/2024
Sonoma Pharmaceuticals, Inc. reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox in the management of urinary tract infections.
-
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
4/4/2024
Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans.
-
AlzeCure Pharma Publishes its Annual Report for 2023
4/4/2024
AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced that its Annual Report for 2023 has been published.
-
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4/4/2024
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK.
-
XVIVO Perfusion AB Publishes Annual Report 2023
4/4/2024
XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2023. The Annual Report is attached to this press release in pdf format and in ESEF format.
-
Results of the Combined General Meeting on April 2, 2024
4/4/2024
Biophytis SA announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting.
-
Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
4/4/2024
Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor.
-
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
4/4/2024
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Year End Financial Results on a Conference Call on April 9, 2024 at 8:30 am Eastern Time.
-
Allara Health Announces New Study That Reveals Significant Productivity Loss Due to Polycystic Ovary Syndrome (PCOS), Highlights Racial and Mental Health Factors
4/3/2024
Allara Health released the first study to investigate the impact of Polycystic Ovary Syndrome (PCOS) on workplace productivity, led by Dr. Heather Huddleston, MD, Director of the University of California San Francisco PCOS Clinic.
-
Berlin Cures Expands Research Capabilities and Scientific Expertise with New Advisory Board
4/3/2024
Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment against Long COVID, appoints six distinguished scientists to a new advisory board.
-
AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024
4/3/2024
AlzeCure Pharma AB announced that an abstract on its preclinical project TrkA-NAM against osteoarthritis pain and other severe pain conditions has been accepted for presentation at the IASP 2024 World Congress on Pain in Amsterdam on August 5-9.
-
Study Shows hTERT Vaccination Induces Immunological Responses and Prevents Progression in a Subset of Therapy-Resistant Poor Prognosis Cancer Patients
4/3/2024
In a significant stride towards active immune therapy of cancer, a recently featured article in Experimental Biology and Medicine (Volume 249, Issue 1) describes a Phase 1 clinical trial, led by James Spicer and colleagues at King's College London.
-
Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization
4/3/2024
Clairvoyant Therapeutics Inc. , today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment.
-
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
4/3/2024
Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), has been published in Nature.
-
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
4/3/2024
Bausch Health, Canada Inc. today announced the first public drug plan listings for Pr UCERIS (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.
-
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
4/3/2024
Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.
-
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis
4/2/2024
Cantargia Cantargia reported publication of promising preclinical data supporting the potential of the anti-IL1RAP antibody CAN10 as treatment of atherosclerosis.